Table 6 Multivariate analysis for patients receiving SRT (n = 2048)
Hazard Ratio | 95% Confidence Interval | p-value | ||
|---|---|---|---|---|
Sex | Male | 1.00 | Ref | 0.001 |
Female | 0.83 | 0.75–0.92 | ||
Age | 18–59 | 1.00 | Ref | 0.058 |
60–69 | 1.07 | 0.95–1.22 | ||
70–79 | 1.2 | 1.04–1.38 | ||
80+ | 1.24 | 0.96–1.58 | ||
Comorbidity | 0 | 1.00 | Ref | 0.062 |
1 | 0.99 | 0.87–1.13 | ||
> 2 | 1.25 | 1.03–1.5 | ||
Histology | Adenocarcinoma | 1.00 | Ref | < 0.001 |
Non-adenocarcinoma | 1.31 | 1.17–1.46 | ||
Race | White | 1.00 | Ref | 0.538 |
Non-white | 1.05 | 0.91–1.21 | ||
Insurance | Uninsured | 1.00 | Ref | 0.582 |
insured | 0.92 | 0.69–1.24 | ||
Facility Type | Academic | 1.00 | Ref | 0.088 |
Nonacademic | 1.1 | 0.99–1.22 | ||
Systemic Therapy | Chemotherapy | 1.00 | Ref | 0.031 |
Immunotherapy | 0.82 | 0.69–0.98 | ||